Drug Development

Health By Andrew Joseph

Huntington’s community grieves not just one therapeutic setback, but two

Biotech By Adam Feuerstein

Sage drug reduces muscle tremor but with significant side effects, study results show

Biotech By Adam Feuerstein

iTeos Therapeutics debuts first data on TIGIT-targeting cancer immunotherapy

Biotech By Adam Feuerstein

Revolution Medicines seeks to bolster case for its lead cancer drug

Biotech By Adam Feuerstein

Natural killer cells, primed with an antibody, induce remissions in patients with advanced blood cancer

Biotech By Adam Feuerstein

Fibrogen admits false heart-safety data for experimental anemia pill shared with FDA, investors

Pharmalot By Ed Silverman

FDA is rebuked by a federal agency for downgrading serious concerns over plant inspections

Biotech By Adam Feuerstein

Data for Delcath’s liver tumor device are positive, but lingering questions cloud path to approval

Pharmalot By Ed Silverman

Most U.S. universities get an ‘F’ on ensuring access to drugs they discover

Biotech By Adam Feuerstein

Uniqure investigation clears hemophilia B gene therapy as cause of patient’s liver cancer

Pharmalot By Ed Silverman

Pfizer hopes for a happy ending for an osteoarthritis drug with a troubled history

Pharmalot By Ed Silverman

Does a drug’s name affect how patients and doctors perceive it? The FDA wants to know

A depiction of Pulmonary ionocytes extending into the respiratory tract of a mouse.

Biotech By Adam Feuerstein

Translate Bio suffers a setback with mRNA-based treatment for cystic fibrosis

Biotech By Adam Feuerstein

A Rubius drug derived from red blood cells produces anti-tumor responses — and more questions

Biotech By Adam Feuerstein

Bluebird says its gene therapy was ‘very unlikely’ to be cause of patient’s cancer

Biotech By Adam Feuerstein

With data on a cancer drug derived from red blood cells looming, Rubius Therapeutics seeks to shed its bumbling image

Pharmalot By Ed Silverman

Drug makers urge Biden to reject proposal to waive patent rights on Covid-19 products

Pharmalot By Ed Silverman

FDA reviews accelerated approvals as two drug makers withdraw bladder cancer indications

Pharmalot By Ed Silverman

European Commission probes Teva for allegedly using patents to thwart competition

Biotech By Adam Feuerstein

Kronos Bio speeds development of genetically targeted leukemia drug with unique trial design

Food And Drug Administration Headquarters 2020 fda hearing

Health Tech By Katie Palmer

FDA releases a new plan to bring its data skills up to speed

First Opinion By Michelle McMurry-Heath

The Biden administration’s pandemic agenda must not ignore superbugs

Biotech By Adam Feuerstein

A surprise FDA advisory panel imperils Fibrogen’s experimental anemia pill

Pharmalot By Ed Silverman

The vial is not half empty: New report lays out ways to address the issue of discarded drugs

Pharmalot By Ed Silverman

Most Read

Lavishly funded Moderna hits safety problems in bold bid to revolutionize medicine

How nanotechnology helps mRNA Covid-19 vaccines work

Thank private risk-taking, not public funding, for Covid-19 vaccines, therapies

Ego, ambition, and turmoil: Inside one of biotech’s most secretive startups

WHO group recommends against using remdesivir to treat hospitalized Covid-19 patients

In a major setback, Merck to stop developing its two Covid-19 vaccines and focus on therapies

The U.S. government doesn’t have patent rights to Gilead’s remdesivir, despite investing millions in research

Ten years after the ‘Berlin patient,’ doctors announce a second person has been effectively ‘cured’ of HIV

All Coverage

Huntington’s community grieves not just one therapeutic setback, but two

Sage drug reduces muscle tremor but with significant side effects, study results show

iTeos Therapeutics debuts first data on TIGIT-targeting cancer immunotherapy

Revolution Medicines seeks to bolster case for its lead cancer drug

Natural killer cells, primed with an antibody, induce remissions in patients with advanced blood cancer

Fibrogen admits false heart-safety data for experimental anemia pill shared with FDA, investors

FDA is rebuked by a federal agency for downgrading serious concerns over plant inspections

Data for Delcath’s liver tumor device are positive, but lingering questions cloud path to approval

Most U.S. universities get an ‘F’ on ensuring access to drugs they discover

Uniqure investigation clears hemophilia B gene therapy as cause of patient’s liver cancer

Pfizer hopes for a happy ending for an osteoarthritis drug with a troubled history

Does a drug’s name affect how patients and doctors perceive it? The FDA wants to know

Translate Bio suffers a setback with mRNA-based treatment for cystic fibrosis

A Rubius drug derived from red blood cells produces anti-tumor responses — and more questions

Bluebird says its gene therapy was ‘very unlikely’ to be cause of patient’s cancer

With data on a cancer drug derived from red blood cells looming, Rubius Therapeutics seeks to shed its bumbling image

Drug makers urge Biden to reject proposal to waive patent rights on Covid-19 products

FDA reviews accelerated approvals as two drug makers withdraw bladder cancer indications

European Commission probes Teva for allegedly using patents to thwart competition

Kronos Bio speeds development of genetically targeted leukemia drug with unique trial design

FDA releases a new plan to bring its data skills up to speed

The Biden administration’s pandemic agenda must not ignore superbugs

A surprise FDA advisory panel imperils Fibrogen’s experimental anemia pill

The vial is not half empty: New report lays out ways to address the issue of discarded drugs

A U.S. court ruling may force biologics makers to review patent protections